Be the first person to write a business review for NPS Pharmaceuticals, Inc.

Nutra Pharma Corporation was founded in 2000 and is based in Boca Raton, Florida. Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. The company, through its subsidiaries, carries out basic drug discovery research and clinical development, and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. Nutra Pharma's wholly-owned drug discovery subsidiary, ReceptoPharm, is developing proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), and Human Immunodeficiency Virus (HIV), and pain in humans. Additionally, ReceptoPharm provides contract research services through its ISO class 5 and GMP certified facilities. The company's wholly-owned medical devices subsidiary, Designer Diagnostics, engages in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases, such Nontuberculous Mycobacteria (NTM). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.

Obagi Medical Products, Inc. company was founded in 1988 and is headquartered in Long Beach, California. Obagi Medical Products, Inc. is a specialty pharmaceutical company focused on the aesthetic and therapeutic skin health markets. The Company develops and commercializes prescription-based products, topical skin health systems that enable physicians to treat a range of skin conditions, including pre-mature aging, photo-damage, hyperpigmentation (irregular or patchy discoloration of the skin), acne, rosacea and soft tissue deficits, such as fine lines and wrinkles. The Company markets and sells a range of systems and related products for the enhancement of skin health. Its principal product line is its Obagi Nu-Derm System. Its Obagi Nu-Derm System is a prescription-based topical skin health system that enhances the skin's overall health by correcting photo damage using drugs that, by definition, work at the cellular level, resulting in a reduction of the visible signs of aging. In January 2009, the Company launched the Obagi Rosaclear System.

Odyssey Thera researches new treatments for cancer and rheumatoid arthritis using its protein-fragment complementation assays (PCAs) to observe the action of small molecules and proteins. Essentially, it works to improve the speed and predictability of the drugs it studies. It technologies expedite the discovery and uses of drugs as well as track the development of new drug therapies. Odyssey partners with large drug makers such as Roche and Pfizer to profile selected compounds across its panel of assays to identify potential lead drug candidates. In 2005 it partnered with Bristol-Myers Squibb to analyze its compounds.

Omnicare Clinical Research is a contract research organization (CRO) offering drug development services, from Phase I to Phase IV clinical trials, to drug and medical device companies worldwide. A unit of nursing home pharmacy operator Omnicare, the CRO has special expertise in the area of geriatrics research and takes advantage of its parent's access to geriatric patient populations and investigators. However, the unit also provides support in numerous other therapeutic areas, including cardiovascular, dermatology, metabolism, and infectious disease. Services include patient and investigator recruitment, drug packaging and distribution, clinical trials management, and medical writing.

Omrix Biopharmaceuticals helps keep blood in its place in the operating room. The company develops biosealants derived from human plasma to control bleeding during surgical procedures. The biosealants contain naturally occurring proteins that clot and adhere to tissue. Johnson & Johnson's Ethicon subsidiary markets and distributes these products under the names Evicel in the US and Quixil in Europe. Omrix's Evithrom thrombin product was developed with Ethicon primarily for neurosurgery. The FDA has approved both for hemostasis (minimizing blood loss) during surgery. Omrix was acquired by Johnson & Johnson in 2008 and became part of the Ethicon division.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.